Biotechnology company Genentech is partnering with Nvidia to accelerate the discovery and development of new medicines using generative AI. The collaboration will optimize Genentech’s proprietary algorithms on Nvidia’s DGX Cloud. Genentech also plans to use Nvidia’s BioNeMo, a platform that simplifies and scales generative AI applications for computational drug discovery.
The initial focus will be on optimizing Genentech’s drug discovery AI models in its “lab in a loop” framework, which aims to understand complex biomolecular patterns and relationships to improve the success rate of R&D. The partnership hopes to streamline the lengthy and complex process of drug discovery and development.
Founded more than 45 years ago, Genentech discovers, develops, and commercializes medicines for serious medical conditions.